{
    "ticker": "MOTI",
    "name": "Motif Bio plc",
    "description": "Motif Bio plc is a biotechnology company focused on developing innovative antibiotic therapies to combat serious infections caused by multi-drug resistant bacteria. Founded in 2016 and headquartered in New York, Motif Bio is committed to addressing the growing public health challenge posed by antibiotic resistance. The company's lead product candidate, iclaprim, is a novel antibiotic targeting Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Iclaprim has shown promising results in clinical trials, demonstrating its potential as a valuable therapeutic option for patients with limited treatment alternatives. Motif Bio is dedicated to advancing its pipeline through rigorous research and development, aiming to deliver safe and effective treatments to healthcare providers and patients. In addition to iclaprim, the company explores other promising compounds and collaborations in the biotech space to expand its portfolio. With a strong focus on innovation and a commitment to addressing unmet medical needs, Motif Bio positions itself as a key player in the fight against antibiotic-resistant infections, striving to improve patient outcomes and public health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, USA",
    "founded": "2016",
    "website": "https://www.motifbio.com",
    "ceo": "Graham L. M. Foster",
    "social_media": {
        "twitter": "https://twitter.com/MotifBio",
        "linkedin": "https://www.linkedin.com/company/motif-bio-plc/"
    },
    "investor_relations": "https://www.motifbio.com/investors",
    "key_executives": [
        {
            "name": "Graham L. M. Foster",
            "position": "CEO"
        },
        {
            "name": "David A. L. W. McNally",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antibiotic Therapies",
            "products": [
                "Iclaprim"
            ]
        }
    ],
    "seo": {
        "meta_title": "Motif Bio plc | Innovating Antibiotic Therapies",
        "meta_description": "Motif Bio plc is focused on developing innovative antibiotics to combat drug-resistant infections. Explore our lead product, iclaprim, and our commitment to public health.",
        "keywords": [
            "Motif Bio",
            "Antibiotics",
            "Biotechnology",
            "Drug Resistance",
            "Iclaprim"
        ]
    },
    "faq": [
        {
            "question": "What does Motif Bio specialize in?",
            "answer": "Motif Bio specializes in developing innovative antibiotic therapies to combat drug-resistant infections."
        },
        {
            "question": "Who is the CEO of Motif Bio?",
            "answer": "Graham L. M. Foster is the CEO of Motif Bio plc."
        },
        {
            "question": "Where is Motif Bio headquartered?",
            "answer": "Motif Bio is headquartered in New York, USA."
        },
        {
            "question": "What is Motif Bio's lead product?",
            "answer": "Motif Bio's lead product is iclaprim, an antibiotic targeting Gram-positive infections."
        },
        {
            "question": "When was Motif Bio founded?",
            "answer": "Motif Bio was founded in 2016."
        }
    ],
    "competitors": [
        "AMRN",
        "PFE",
        "MRNA",
        "GILD"
    ],
    "related_stocks": [
        "JNJ",
        "ABBV",
        "BMY",
        "AZN"
    ]
}